Overview

A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of RO7198457 plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Collaborators:

Biontech AG
BioNTech SE

Treatments:

Pembrolizumab